NeuroDerm Initiates Phase 2 Study Of ND0801 In Patients With ADD/ADHD

Links shared publicly online about this topic.

  • 737
    total visits

NeuroDerm Initiates Phase 2 Study Of ND0801 In Patients With ADD/ADHD

medicalnewstoday.com —

NeuroDerm, Ltd. announced that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Di

View full resource at medicalnewstoday.com

Tags: ADHD, Phase 2 Clinical Trial

  • Share

Most Recently Shared on November 10, 2010 at 9:05 pm By:

mnt_clinical MNT Clinical Trials

NeuroDerm Initiates Phase 2 Study Of ND0801 In Patients With ADD/ADHD http://mnt.to/3Mmr #clinicaltrials

1 year ago...

Reply

Retweet

Favorite

Also Shared By:

MNT ADHD & ADD News MNT ADHD & ADD News

MNT Pharma News MNT Pharma News

Advertisement